Hematopoietic SCT in patients with a history of invasive fungal infection

P. Zhang, A. Song, Zack Z. Wang, S. Feng, L. Qiu, M. Han

Research output: Contribution to journalArticle

Abstract

Earlier invasive fungal infections (IFI) put recipients of hematopoietic SCT (HSCT) at a high risk of IFI-related mortality. We retrospectively assessed the feasibility of HSCT for patients with a history of IFI and the efficacy of secondary prophylaxis. From January 2001 to December 2007, 49 patients with a history of IFI underwent HSCT and most of them received broad-spectrum antifungal agents as secondary prophylaxis. After a median follow-up of 355 days (15-967), nine patients experienced failure of IFI prophylaxis, including three cases of IFI-related death, leading to a 2-year cumulative incidence of 18.4 and 6.1%, respectively. Four risk factors for the failure of prophylaxis were found, namely time interval from the diagnosis of IFI to transplantation, residual diseases before transplantation, infection with CMV and use of corticosteroid for the treatment of GVHD. A similar outcome can be achieved in recipients of Auto- and Auto-HSCT. Despite a higher risk of post-transplant progression, residual features of IFI did not affect the overall outcome of HSCT. In conclusion, a history of IFI and residual features are not contraindications to HSCT and secondary prophylaxis by broad-spectrum antifungal agents can protect patients from relapse or progression of an earlier infection.

Original languageEnglish (US)
Pages (from-to)533-537
Number of pages5
JournalBone Marrow Transplantation
Volume43
Issue number7
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Antifungal Agents
Transplantation
Invasive Fungal Infections
Infection
Adrenal Cortex Hormones
Transplants
Recurrence
Mortality
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Hematopoietic SCT in patients with a history of invasive fungal infection. / Zhang, P.; Song, A.; Wang, Zack Z.; Feng, S.; Qiu, L.; Han, M.

In: Bone Marrow Transplantation, Vol. 43, No. 7, 2009, p. 533-537.

Research output: Contribution to journalArticle

Zhang, P. ; Song, A. ; Wang, Zack Z. ; Feng, S. ; Qiu, L. ; Han, M. / Hematopoietic SCT in patients with a history of invasive fungal infection. In: Bone Marrow Transplantation. 2009 ; Vol. 43, No. 7. pp. 533-537.
@article{60eb1a1a4fa04c019e7cfb08cd488fcc,
title = "Hematopoietic SCT in patients with a history of invasive fungal infection",
abstract = "Earlier invasive fungal infections (IFI) put recipients of hematopoietic SCT (HSCT) at a high risk of IFI-related mortality. We retrospectively assessed the feasibility of HSCT for patients with a history of IFI and the efficacy of secondary prophylaxis. From January 2001 to December 2007, 49 patients with a history of IFI underwent HSCT and most of them received broad-spectrum antifungal agents as secondary prophylaxis. After a median follow-up of 355 days (15-967), nine patients experienced failure of IFI prophylaxis, including three cases of IFI-related death, leading to a 2-year cumulative incidence of 18.4 and 6.1{\%}, respectively. Four risk factors for the failure of prophylaxis were found, namely time interval from the diagnosis of IFI to transplantation, residual diseases before transplantation, infection with CMV and use of corticosteroid for the treatment of GVHD. A similar outcome can be achieved in recipients of Auto- and Auto-HSCT. Despite a higher risk of post-transplant progression, residual features of IFI did not affect the overall outcome of HSCT. In conclusion, a history of IFI and residual features are not contraindications to HSCT and secondary prophylaxis by broad-spectrum antifungal agents can protect patients from relapse or progression of an earlier infection.",
author = "P. Zhang and A. Song and Wang, {Zack Z.} and S. Feng and L. Qiu and M. Han",
year = "2009",
doi = "10.1038/bmt.2008.356",
language = "English (US)",
volume = "43",
pages = "533--537",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Hematopoietic SCT in patients with a history of invasive fungal infection

AU - Zhang, P.

AU - Song, A.

AU - Wang, Zack Z.

AU - Feng, S.

AU - Qiu, L.

AU - Han, M.

PY - 2009

Y1 - 2009

N2 - Earlier invasive fungal infections (IFI) put recipients of hematopoietic SCT (HSCT) at a high risk of IFI-related mortality. We retrospectively assessed the feasibility of HSCT for patients with a history of IFI and the efficacy of secondary prophylaxis. From January 2001 to December 2007, 49 patients with a history of IFI underwent HSCT and most of them received broad-spectrum antifungal agents as secondary prophylaxis. After a median follow-up of 355 days (15-967), nine patients experienced failure of IFI prophylaxis, including three cases of IFI-related death, leading to a 2-year cumulative incidence of 18.4 and 6.1%, respectively. Four risk factors for the failure of prophylaxis were found, namely time interval from the diagnosis of IFI to transplantation, residual diseases before transplantation, infection with CMV and use of corticosteroid for the treatment of GVHD. A similar outcome can be achieved in recipients of Auto- and Auto-HSCT. Despite a higher risk of post-transplant progression, residual features of IFI did not affect the overall outcome of HSCT. In conclusion, a history of IFI and residual features are not contraindications to HSCT and secondary prophylaxis by broad-spectrum antifungal agents can protect patients from relapse or progression of an earlier infection.

AB - Earlier invasive fungal infections (IFI) put recipients of hematopoietic SCT (HSCT) at a high risk of IFI-related mortality. We retrospectively assessed the feasibility of HSCT for patients with a history of IFI and the efficacy of secondary prophylaxis. From January 2001 to December 2007, 49 patients with a history of IFI underwent HSCT and most of them received broad-spectrum antifungal agents as secondary prophylaxis. After a median follow-up of 355 days (15-967), nine patients experienced failure of IFI prophylaxis, including three cases of IFI-related death, leading to a 2-year cumulative incidence of 18.4 and 6.1%, respectively. Four risk factors for the failure of prophylaxis were found, namely time interval from the diagnosis of IFI to transplantation, residual diseases before transplantation, infection with CMV and use of corticosteroid for the treatment of GVHD. A similar outcome can be achieved in recipients of Auto- and Auto-HSCT. Despite a higher risk of post-transplant progression, residual features of IFI did not affect the overall outcome of HSCT. In conclusion, a history of IFI and residual features are not contraindications to HSCT and secondary prophylaxis by broad-spectrum antifungal agents can protect patients from relapse or progression of an earlier infection.

UR - http://www.scopus.com/inward/record.url?scp=64949114058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949114058&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.356

DO - 10.1038/bmt.2008.356

M3 - Article

C2 - 19104496

AN - SCOPUS:64949114058

VL - 43

SP - 533

EP - 537

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -